Selling US Grown Flower to Europe: What the Margin Actually Says

Written by Michael Sassano, Founder and Interim CEO, SOMAÍ Pharmaceuticals

Most US cannabis companies thinking about Europe focus on the wrong number. They see €6/gram in Germany, £8 at a UK clinic, or AUD$10 in an Australian dispensary, run a quick currency conversion, and conclude the margin is a goldmine.

Let’s look at the facts: it isn’t – not unless you deeply understand the channel.

Whether Europe works for your company depends on three brutal questions:

1. Do you have excess capacity? No surplus, no trade case—build a strong margin EU vertical instead.
2. Are you vertically integrated at home? If yes, the only model that successfully replicates your economics in Europe is owning the vertical there too.
3. Is your U.S. wholesale price materially below European importer prices? This is the only scenario where trading alone makes sense, and even then, you will still need distribution infrastructure on the European side.

There is one massive constraint across all these markets: EU-GMP certification. No EU-GMP means absolutely no pharmacy access in Germany, the UK, or Australia. Germany is also moving toward blocking GACP-to-GMP conversions, so smart operators should assume that window is rapidly closing.

🇩🇪 Germany: The Channel Squeeze

Germany is the largest open cannabis market in Europe. As of July 2026, state insurance no longer covers cannabis flowers — self-pay is now the entire market.

• The Reality: A US seller receives at importer level: €0.75–1.75/gram for greenhouse ($0.81–1.89), €1.75–3.75/gram for indoor ($1.89–4.05).
• The Patent Cost: The patient pays: €2.50–4.00/gram for greenhouse, €5.00–8.00/gram for indoor. The Bloomwell Cannabis Barometer put the self-pay average at €4.52/gram in Q1 2026 — 60% of products below €4.00/gram.
• The Leakage: Between importer and patient: a distributor taking 15–25%, a pharmacy adding 30–50% under the AMPreisV ordinance, clinics earning 5–12% in marketing fees.
• The Bottom Line: The channel takes 45–62% of retail. The seller keeps the rest.

Germany: price stack from seller to patient (EUR/g). USD equivalent in bars.

🇬🇧 United Kingdom: The Private Prescription Hurdle

The UK runs on private prescription routed through clinic networks to specialist pharmacies. There is no insurance; every purchase is out-of-pocket.

• The Reality: Importer prices: £0.90–2.00/gram greenhouse ($1.14–2.54), £2.00–3.25/gram indoor ($2.54–4.13).
• Patient Cost: Patient retail for mainstream product: £6.50–8.00/gram, with a verified average of £6.95/gram in December 2025. Budget product runs £3.95–5.50/gram. Top shelf reaches £10–13/gram — not where the volume sits.
• The Leakage: Distributor taking 20% depending on clinic access, a pharmacy is only around 15%, while clinics can control 40-60% depending on distribution access.
• The Bottom Line: Distribution, clinic, and pharmacy combined take 64–74% of what the patient pays.

UK: price stack from seller to patient (GBP/g). USD equivalent in bars.

READ MORE…

🇦🇺 Australia: Low Prices, Easy Access

Australia pays the lowest wholesale prices of the three markets and has the most easy access pathway. TGA accepts almost any country certification. Most volume runs through Authorised Prescribers. The market is dominated by vertically integrated operators.

• The Reality: Importer prices: AUD$1.50–2.00/gram greenhouse ($0.98–1.30), AUD$2.50–4.00/gram indoor ($1.63–2.60).
• Patient Cost: Patient retail: AUD$4.60–6.60/gram for greenhouse, AUD$8.00–12.00/gram for indoor mainstream. The floor has dropped to AUD$3.30/gram — 39% of SKUs now priced below AUD$10.
• The Leakage: Distributor margin runs 10–35% by volume tier. Pharmacies charge a flat AUD$15–20 dispensing fee per package — targeting 20%. Clinics earn around 20-50% of wholesale via ESSA agreements.
• The Bottom Line: The channel takes 54–69% of retail. 

Australia: price stack from seller to patient (AUD/g). USD equivalent in bars.

🇺🇸 The US Baseline

California outdoor growers today sell at $0.66–0.88/gram — below their all-in cost of $0.92/gram. Cultivation, mandatory testing, and excise tax leave most selling at a loss. Many are exiting. Greenhouse reaches $1.10–1.65/gram, indoor $1.65–2.20/gram.

Own the dispensary and the picture changes. Greenhouse 1/8ths sell for $20–40 at retail ($5.71–11.43/gram). Indoor 1/8ths at $35–60 ($10.00–17.14/gram). The dispensary captures 45–55% gross margin. Without it, the grower captures 7–11% of shelf price.

Limited-licence states show a different model. Ohio averages $6.59/gram retail. New Jersey and New York: $7–10/gram. Florida MSO medical: $8–12/gram. Florida operators are legally required to be vertically integrated — grow, process, and sell. They capture the full chain. Zero channel leakage.

What the Comparison Shows

The chart below converts all markets to USD. Two bars per segment: what the seller receives and what the patient pays. The figure on the right is the percentage that stays in the channel.

All markets — seller price vs. patient retail in USD. FX approx. mid-2026: EUR $1.08 | GBP $1.27 | AUD $0.65. California retail = licensed dispensary pricing. Ohio and NJ/NY seller = estimated wholesale.

EU and Australian retail in USD is lower than California premium dispensary pricing. Ohio and NJ/NY retail ($6–10/gram) is broadly comparable to Germany and UK retail in USD. The difference is not the retail price. The difference is how much of the chain the operator owns.

Florida makes the point cleanly: 0% to the channel. The operator is the channel.

Trading or Building – The Right Question

There are two operator types and two different answers.

If you are a large California outdoor grower drowning below cost, trading into Europe is a lifeline. EU greenhouse importer prices are comparable to or better than the home market in USD terms, and your domestic alternative is structural decline.

However, if you are a limited-license indoor operator already earning $7–12/gram with a dispensary, selling to a European distributor for $2.97 (USD) is a massive step backwards. You are taking on GMP certification, new regulatory burdens, and currency exposure for a fraction of your domestic margin. For you, trading does not work.

Building a Vertical in Europe

Fully vertical European operators significantly outperform U.S. multi-state operators, since EU cannabis companies with vertical integrated access command pharmaceutical-grade EBITDA margins (typically 30–50%) and larger valuation multiples. Additionally:

• There is no 280E.
• There are no special state assessed grow taxes.
• There are no banking restrictions.
• There are no state-by-state licensing walls to restrict economies of scale.

A single EU-GMP facility can service Germany, the UK, Australia, and emerging markets from one infrastructure base. That operating leverage does not exist in the U.S. model.

U.S. MSOs are built on regulatory arbitrage within state borders. European verticals are built on pharmaceutical infrastructure that is genuinely hard to replicate. That is the moat, and that is the multiple.

Trading in Europe is a short-term arbitrage play. Building in Europe is a business. The margin stays in the channel unless you own it.

Sources: *interviews; California DCC dashboard (Nov 2025); StratCann / GCX Fall 2025 Global Cannabis Report; Leven Therapeutics Q2 2025 investor disclosure; Bloomwell Cannabis Barometer Q1 2026; Medbud.wiki Dec 2025; Cannabiz / honahlee 2025; BusinessOfCannabis.com (Jul 2026 GKV ban); CDTFA AMP benchmark; Cannabis Business Times / Ohio CRA 2025. FX rates approximate mid-2026.